Loading organizations...
Key people at Becker Ventures.
Becker Ventures operates as a family-owned and operated private equity firm, strategically deploying capital across various industries. The firm functions as a diversified conglomerate, primarily holding investments within manufacturing, real estate, and service sectors. It emphasizes active management and long-term value creation across its portfolio companies, seeking to enhance operational efficiencies and market positioning.
The company was founded as a family-owned entity, maintaining a legacy rooted in entrepreneurial spirit and investment acumen passed through generations. While specific founding details such as names and precise dates are not readily available, the firm’s operational structure suggests a deep commitment to stewardship and sustainable growth. Its foundational insight likely centered on identifying and nurturing opportunities within established asset classes.
Becker Ventures partners with businesses across its target sectors, providing essential capital and strategic oversight to catalyze growth and expansion. The firm's core vision revolves around building enduring value by fostering operational excellence and expanding market presence within its diverse holdings. It aims to achieve consistent returns through careful asset management and strategic development for the long term.
Key people at Becker Ventures.
Becker Ventures has 4 tracked investments across 4 companies. The latest tracked deal is $3.0M Seed in NEXST in March 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 11, 2026 | NEXST | $3.0M Seed | — | Castrum Capital, M2M Capital, TBV |
| Dec 10, 2025 | Amplifold | $5.8M Seed | Benedikt Kronberger, Stephan Huber | Dominic Thiem, Ilkay Gündoğan, Joshua Kimmich, Marc Aurel Boersch, Michael (mic) Weigl, Prof. DR. Stefan Tewes, Monika Steger, Btov Partners |
| Oct 1, 2018 | Velicept Therapeutics | $15.0M Series B | Samsara BioCapital | CDK Associates, Fountain Healthcare Partners, Longitude Capital |
| Dec 1, 2017 | Atox Bio | $30.0M Series F | Jonathan Tobin | Brandon Capital Partners, Terry Gould, Asahi Kasei, Integra Holdings, Lundbeckfond Ventures, OrbiMed, SR ONE |